[1] Tod M. Isepamicin in intensive care unit patients with nosocomial pneumonia: population pharmacokinetic-pharmacodynamic study[J]. J A ntimicrob Chemother, 1999, 44: 99-108. [2] Morin J P, Bendirdjian J P, Pillastre A, et al. Interference of fosf-omycin with lysosomal membrane integrity of rat kidney cells[J]. Drugs Exptl Clin Res, 1978, 4: 63. [3] LIANG J J, TANG Q Y. Fosfomycin could reduce other drug-induced adverse reactions[J].World Notes on Antibiotics, 2002, 23 (1): 38-40. [4] FANG X Q, LIU Y N, WANG R et al. Synergism of bactericidal activities of fleroxacin combined with azithromyicn in the treatment of local infection caused by P. aeruginosa[J]. Chin J Nosocomiol, 2002, 12(7): 507-509. [5] ZHANG Q G, LIU Y N, WANG R. Comparison of antibacterial activity, ototoxicity and nephrotoxicity of amikacin between once-daily and twice-daily regimen in the guinea pig[J]. Natl Med J China, 2002, 3: 82(5). [6] Rebecca L, Delegge, Mark H, et al. Percutaneous endoscopic gastrostomy evaluation of device materials: are we “Failsafe”?[J]. Nutr Clin Pract, 2005, 20: 613-617. [7] PEI F, LI C F, WANG R. Therapy of bacterial biofilm drug resistant-shield and associated-infection[J]. Chin J New Drugs, 2003, 12(1): 19-22. [8] FAN Y, PEI F, LIANG B B et al. The study on the antibacterial activity of fosfomycin combined with five aminoglycosides against pseudomonas aeruginosa[J]. Chinese Journal of Drug Application and Monitoring,2007,4(1):47-49. [9] Tod M. Isepamicin in intensive care unit patients with nosocom- ialpneumonia:population pharmacokinetic2pharmacodynamic study[J]. J A ntimicrob Chemother ,1999 ,44 :992108. [10] D Amico Gitseppe, Bazz Claudio. Vrinary protein and enzyme excretion as markers of tubular damage[J]. Current Opinion in Nepholcgy and Hy2 pertension ,2003 ,12 :639 - 643. |